These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30040005)

  • 1. Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario.
    Grootendorst P; Shim M; Falconi A; Robinson T; Lexchin J
    Int J Health Serv; 2018 Oct; 48(4):702-715. PubMed ID: 30040005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.
    Lexchin J
    Value Health; 2017 Sep; 20(8):1139-1142. PubMed ID: 28964446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How complete are drug history profiles that are based on public drug benefit claims?
    Paterson JM; Suleiman A; Hux JE; Bell C
    Can J Clin Pharmacol; 2008; 15(1):e108-16. PubMed ID: 18283220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Position and enforcement practice of the People's Republic of China's pharmaceutical data exclusivity protection.
    Li N; Yu X; Pecht M
    Drug Des Devel Ther; 2016; 10():2015-20. PubMed ID: 27382254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raising the Barriers to Access to Medicines in the Developing World - The Relentless Push for Data Exclusivity.
    Diependaele L; Cockbain J; Sterckx S
    Dev World Bioeth; 2017 Apr; 17(1):11-21. PubMed ID: 26818105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.
    Lexchin J
    Int J Risk Saf Med; 2015; 27(3):135-42. PubMed ID: 26410247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Method for Approximating Future Entry of Generic Drugs.
    Beall RF; Darrow JJ; Kesselheim AS
    Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades.
    Amin T; Kesselheim AS
    Health Aff (Millwood); 2012 Oct; 31(10):2286-94. PubMed ID: 23048110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canada's Patented Medicines (Notice of Compliance) Proceedings and Intellectual Property.
    Bian H; McCourt C
    Cold Spring Harb Perspect Med; 2015 Jan; 5(6):. PubMed ID: 25573772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection].
    Lipschitz Y; Tamir O; Shemer J
    Harefuah; 2004 Dec; 143(12):845-8, 912. PubMed ID: 15666700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
    Zhang W; Sun H; Guh D; Anis AH
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the pharmaceutical market in Bulgaria innovative?
    Stoimenova A; Stankova M; Samev K; Petrova G
    Boll Chim Farm; 2003 Sep; 142(7):260-3. PubMed ID: 14677267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.
    Zhang W; Guh D; Sun H; Marra CA; Lynd LD; Anis AH
    Med Care; 2016 Sep; 54(9):884-90. PubMed ID: 27213540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A trade agreement's impact on access to generic drugs.
    Shaffer ER; Brenner JE
    Health Aff (Millwood); 2009; 28(5):w957-68. PubMed ID: 19706626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.